SURF4 and Hypercholesterolemia: Taken together with the marked reductions in plasma cholesterol associated with genetic or therapy-induced reductions in plasma PCSK9 (ODYSSEY LONG TERM Investigators et al., 2015), our findings raise the possibility that SURF4 could represent an additional novel therapeutic target for the treatment of hypercholesterolemia.